# Impact of moderate-to-severe coronary calcification on 1-year clinical outcomes after IVUS-guided PCI

**Authors:** Thanh Cong Nguyen, Vu Hoang Vu, Bao Thien Duong, Hoa Tran, Khoi Minh Le, Hung Minh Ngo, Van Hoang, Thai Quoc Nguyen, Binh Quang Truong

PMC · DOI: 10.3389/fcvm.2026.1720958 · Frontiers in Cardiovascular Medicine · 2026-02-06

## TL;DR

This study finds that moderate-to-severe coronary calcification does not worsen clinical outcomes after IVUS-guided PCI when adjustments are made.

## Contribution

The study provides new evidence on the clinical relevance of coronary calcification in modern IVUS-guided PCI procedures.

## Key findings

- Moderate-to-severe CAC was not significantly associated with MACE after adjustment.
- MACE rates were comparable between moderate-to-severe and none/mild CAC groups in the matched cohort.
- Stent thrombosis and target lesion revascularization rates were low and similar across groups.

## Abstract

Moderate-to-severe coronary artery calcification (CAC) poses major challenges during percutaneous coronary intervention (PCI) and has historically been associated with procedural failure and adverse outcomes. However, its prognostic relevance in the era of contemporary intravascular imaging–guided PCI remains uncertain. This study aimed to evaluate the impact of moderate-to-severe CAC on 1-year clinical outcomes after IVUS-guided PCI.

This prospective, single-center study enrolled 914 patients who underwent IVUS-guided PCI between March and November 2023. CAC severity was classified by IVUS as none/mild or moderate-to-severe. After 1:1 propensity score matching, 576 patients (288 per group) were included. The primary endpoint was 1-year major adverse cardiac events (MACE), defined as a composite of all-cause death, myocardial infarction, and target lesion revascularization.

Moderate-to-severe CAC was present in 37.0% of patients. Before matching, the 1-year MACE rate was higher in patients with moderate-to-severe CAC than in those with none/mild CAC (9.5% vs. 4.2%; p = 0.001). In the matched cohort, this difference was attenuated and no longer statistically significant (9.4% vs. 6.3%; p = 0.162). Moderate-to-severe CAC was not significantly associated with MACE (HR 1.54; 95% CI 0.85–2.79; p = 0.157). Rates of stent thrombosis and target lesion revascularization were low and comparable.

Under routine IVUS-guided PCI, moderate-to-severe coronary calcification was associated with 1-year clinical outcomes comparable to those of no or mild calcification after adjustment.

## Linked entities

- **Diseases:** myocardial infarction (MONDO:0005068)

## Full-text entities

- **Diseases:** ACS (MESH:D000168), MACE (MESH:D002318), HDDD (OMIM:607485), Myocardial Infarction (MESH:D009203), atrial fibrillation (MESH:D001281), cardiac death (MESH:D003643), saphenous vein graft lesions (MESH:D055589), hypertension (MESH:D006973), stent thrombosis (MESH:D013927), restenosis (MESH:D023903), calcified (MESH:D018333), Coronary (MESH:D003323), CAC (MESH:D003324), peripheral artery disease (MESH:D058729), -elevation (MESH:D006937), heart failure (MESH:D006333), chronic kidney disease (MESH:D051436), NSTEMI (MESH:D000072658), cardiogenic shock (MESH:D012770), calcification (MESH:D002114), three-vessel disease (MESH:C536223), diabetes (MESH:D003920), dyslipidemia (MESH:D050171), Coronary lesion (MESH:D003327), Acute coronary syndrome (MESH:D054058), COPD (MESH:D029424), stroke (MESH:D020521), TLR (MESH:D009059), ST-segment elevation myocardial infarction (MESH:D000072657)
- **Chemicals:** ACEi (-), calcium (MESH:D002118), MRA (MESH:C502936)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12920530/full.md

## Figures

3 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12920530/full.md

## References

30 references — full list in the complete paper: https://tomesphere.com/paper/PMC12920530/full.md

---
Source: https://tomesphere.com/paper/PMC12920530